Novel agents for the treatment of pancreatic adenocarcinoma

Journal of the Pancreas

Volumn 12, Issue 4, 2011, Pages 334-338

  Cheng, Haiying ^a   Merika, Eirini ^b   Syrigos, Kostas N ^c   Saif, Muhammad Wasif ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Adenocarcinoma; Checkpoint kinase 1; Checkpoint kinase 2; Clinical Trials; Hedgehog Proteins; Pancreatic Neoplasms; Phase I as Topic adverse effects; Protein Kinases; Protein Serine Threonine Kinases

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; AZD 7762; BAY 80 6946; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; GEMCITABINE; IPI 926; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VISMODEGIB;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DYSGEUSIA; ENZYME INHIBITION; FATIGUE; FEVER; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; IONIZING RADIATION; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER DYSFUNCTION; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MUCOSA INFLAMMATION; MUSCLE SPASM; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PERIPHERAL EDEMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHICAGO; CONGRESSES AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; SOCIETIES, MEDICAL; UNITED STATES;

EID: 79960266140     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hidalgo M. Pancreatic cancer. N Engl J Med; 362:1605-17.
2. Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 2011;12(1):8-9.
3. Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med 2009; 361:2094-6.
4. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-6.
5. Olson P, Hanahan D. Cancer. Breaching the cancer fortress. Science 2009; 324:1400-1.
6. Tremblay MR, Lescarbeau A, Grogan MJ, Tan E, Lin G, Austad BC, et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009; 52: 4400-4418.
7. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-61.
8. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basalcell carcinoma. N Engl J Med 2009; 361:1164-72.
9. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-8.
10. Stephenson J, Wolpin BM, Becerra C, Hamm JT, Messersmith WA, Devens S, et al. The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 2011; 29(Suppl.):4114.
11. Rudin AJ, Miller WH Jr., Eigl BJ, Gettinger SN, Chang AL, Faia K, et al. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. J Clin Oncol 2011; 29(Suppl.):3014.
12. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci; 32: 308-316.
13. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7: 2955-2966.
14. Sausville EA, Carducci MA, Barker PM, Agbo F, Oakes P, Senderowicz AM. Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. J Clin Oncol 2011; 29(Suppl.):3058.
15. Falasca M, Selvaggi F, Buus R, Sulpizio S, Edling CE. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer - from molecular signalling to clinical trials. Anticancer Agents Med Chem 2011;11: 455-463.
16. Parsons CM, Muilenburg D, Bowles TL, Virudachalam S, Bold RJ. The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Res. 2010; 30(9):3279-89.
17. Sun C, Rosendahl AH, Andersson R, Wu D, Wang X. The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer. Pancreatology. 2011;27:252-60.
18. Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267:2003-6.
19. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19: 2324-2330.
20. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-1092.
21. Patnaik A, Mountz JM, Ramanathan RK, Beeram M, Tolcher AW, Papadopoulos KP, et al. A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase. J Clin Oncol 2011; 29(Suppl.):3035.
22. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005;24(50):7391-3.